Fast-Acting Solutions: A Comprehensive Review Of Immediate Release Oral Contraceptive Dosage Forms
Keywords:
Oral Contraceptives, Excipient Selection, Solubilizing Agents, Drug Absorption, Contraceptive Efficacy.Abstract
This comprehensive review explores the advancements and challenges associated with immediate release (IR) oral contraceptive dosage forms, which are pivotal in modern contraceptive therapy. Oral contraceptives, including combined oral contraceptives (COCs) and progestin-only pills (POPs), are widely utilized for their efficacy in preventing pregnancy through hormonal modulation. The evolution of these formulations has led to the development of low-dose and ultra-low-dose regimens that minimize adverse effects while maintaining contraceptive effectiveness. IR dosage forms are designed to ensure rapid disintegration and absorption of active pharmaceutical ingredients (APIs), achieving peak plasma concentrations within 1-2 hours post-ingestion. This rapid onset is crucial for effective ovulation suppression, particularly in emergency contraception scenarios. The review highlights the importance of excipient selection, including superdisintegrants and solubilizing agents, which enhance the bioavailability and dissolution rates of poorly soluble APIs like ethinylestradiol and levonorgestrel.Despite their advantages, IR formulations face challenges such as the need for strict adherence to dosing schedules and the impact of first-pass metabolism on bioavailability. The review also discusses regulatory considerations, including quality control measures and bioequivalence studies, which are essential for ensuring the safety and efficacy of these contraceptives. Furthermore, it identifies knowledge gaps and proposes future directions for optimizing IR formulations to improve user convenience and therapeutic outcomes in oral contraceptive regimens.This review serves as a valuable resource for healthcare professionals, researchers, and pharmaceutical developers aiming to enhance the effectiveness and accessibility of oral contraceptive therapies.
Downloads
References
1. Glasier A. Contraception. In: Berek JS, editor. Berek & Novak’s Gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 267–85.
2. Kaunitz AM. Oral contraceptives: patterns of use. Obstet Gynecol Clin North Am. 2007;34(4):635–49.
3. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in real-life usage. Int J Womens Health. 2014;6:201–8.
4. Burkman R. Oral contraceptives: current status. Clin Obstet Gynecol. 2010;53(4):749–57.
5. World Health Organization. WHO Model List of Essential Medicines – 22nd List, 2021. Geneva: WHO; 2021.
6. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338(16):1128–37.
7. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–96.
8. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002;3(3):211–24.
9. Sweetman SC, editor. Martindale: The Complete Drug Reference. 37th ed. London: Pharmaceutical Press; 2011.
10. Kaunitz AM. Progestin-only oral contraceptives: An overview. Am J Obstet Gynecol. 1998;179(3):S1–S6.
11. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 μg versus >20 μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2008;(4):CD003989.
12. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(12):865–83.
13. Burkman RT. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185(2):S4–S12.
14. Speroff L, Darney PD. A Clinical Guide for Contraception. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
15. Glasier A. Contraception. In: Berek JS, editor. Berek & Novak’s Gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 267–85.
16. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems and oral contraceptive pills. Obstet Gynecol Sci. 2018;61(5):485–497.
17. Stanczyk FZ, Archer DF. Duration of action of injectable contraceptives. Curr Opin Obstet Gynecol. 2003;15(5):395–401.
18. US Food and Drug Administration (FDA). Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations. Silver Spring: FDA; 2014.
19. Stanczyk FZ, Archer DF. Duration of action of hormonal contraceptives. Curr Opin Obstet Gynecol. 2003;15(5):395–401.
20. Glasier A. Emergency contraception. BMJ. 1997;314(7092):776–779.
21. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in real-life usage. Int J Womens Health. 2014;6:201–208.
22. Sweetman SC, editor. Martindale: The Complete Drug Reference. 37th ed. London: Pharmaceutical Press; 2011.
23. Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS. Contraceptive Technology. 20th rev. ed. New York: Ardent Media; 2011.
24. Stanczyk FZ, Archer DF. Duration of action of hormonal contraceptives. Curr Opin Obstet Gynecol. 2003;15(5):395–401.
25. Kuhnz W, Gansau C, Mahler M, Hümpel M. Pharmacokinetics of ethinylestradiol in women. Contraception. 1992;46(6):537–548.
26. Kaunitz AM. Oral contraceptive adherence: issues and strategies. Am J Obstet Gynecol. 1999;180(6 Pt 2):S33–S36.
27. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404.
28. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet. 1990;18(6):472–484.
29. Brache V, Faundes A. Contraceptive efficacy of the LNG-IUS and other methods. Int J Gynaecol Obstet. 2013;123(Suppl 3):S30–S35.
30. Kolhe P, Patil S, Chopade P, et al. Design and development of controlled release tablets of antihypertensive drug. Int J Pharm Pharm Sci. 2013;5(4):395–398.
31. Hede R, Goycoolea FM. Disintegrants in tablets. In: Lachman L, Liberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea & Febiger; 1986. p. 175–179.
32. Mehta S, Pawar S, Gangwal S, et al. Solid dosage form: A practical approach to oral drug delivery. In: Jain N, editor. Pharmaceutical Dosage Forms: Tablets. 2nd ed. Vol. 2. New York: Marcel Dekker Inc; 2003. p. 763–789.
33. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017–1025.
34. Rowe RC, Sheskey PJ, Weller PJ. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.
35. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. 1st ed. New Delhi: Vallabh Prakashan; 2002.
36. Kamboj S, Mittal A, Kumawat M. Direct Compression: A Novel Approach to Tablet Formulation. J Pharm Bioallied Sci. 2012;4(1):9–15.
37. Kumar R, Sharma R. Advances in direct compression technology. Int J Pharm Tech Res. 2010;2(2):1713–1719.
